Werewolf Therapeutics, Inc.
NASDAQ:HOWL
2.34 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 19.943 | 16.401 | 0 | 0 | 0 |
| Cost of Revenue
| 1.764 | 2.51 | 0.735 | 0.777 | 0.463 |
| Gross Profit
| 18.179 | 13.891 | -0.735 | -0.777 | -0.463 |
| Gross Profit Ratio
| 0.912 | 0.847 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 41.776 | 53.761 | 35.269 | 16.641 | 6.34 |
| General & Administrative Expenses
| 18.67 | 18.696 | 14.818 | 5.763 | 3.596 |
| Selling & Marketing Expenses
| -1.764 | 0 | 0 | 0 | 0 |
| SG&A
| 16.906 | 18.696 | 14.818 | 5.763 | 3.596 |
| Other Expenses
| -1.142 | 2.246 | 0.104 | 7.263 | 0.43 |
| Operating Expenses
| 58.682 | 72.457 | 50.087 | 22.404 | 9.936 |
| Operating Income
| -40.503 | -56.056 | -50.087 | -22.404 | -9.936 |
| Operating Income Ratio
| -2.031 | -3.418 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 3.135 | 2.246 | 0.104 | 7.364 | -0.312 |
| Income Before Tax
| -37.368 | -53.81 | -49.983 | -15.04 | -10.248 |
| Income Before Tax Ratio
| -1.874 | -3.281 | 0 | 0 | 0 |
| Income Tax Expense
| 1.596 | -2.246 | -0.216 | -0.101 | 0.742 |
| Net Income
| -37.368 | -51.564 | -49.767 | -14.939 | -10.99 |
| Net Income Ratio
| -1.874 | -3.144 | 0 | 0 | 0 |
| EPS
| -1.05 | -1.79 | -1.82 | -0.52 | -0.38 |
| EPS Diluted
| -1.05 | -1.79 | -1.82 | -0.52 | -0.38 |
| EBITDA
| -38.739 | -56.056 | -50.087 | -22.254 | -9.541 |
| EBITDA Ratio
| -1.942 | -3.418 | 0 | 0 | 0 |